Home About Us Our Technology Pipeline OTLERTUZUMAB (anti-CD37) MOR209/ES414 (anti-PSMA x anti-CD3) APVO425 (anti-ROR1 x anti-CD3) Alzheimer’s Disease Immunotherapy (5E3/cSNK technology) Other Candidates IXINITY® Investors Stock Details News Events Presentations SEC Filings Corporate Governance Investor FAQs Careers Contact Privacy Terms of Use
